We are glad to announce that Aagami has a new client which is focused on rare disease. Aagami shall assist the client for possible sale, di...
Published : 07 Apr 2025
Read MoreWe are pleased to announce a new client win. The client is a California based company with Phase 3 stage small molecule eye drop to treat pre-surgical...
Published : 27 Mar 2025
Read MoreWe have a new Client - An Illinois company developing innovative therapies for resuscitation from sudden cardiac arrest has appointed Aagami to suppor...
Published : 15 Feb 2025
Read MoreAagami has been appointed as Advisory, Marketing and Sales Consultant to Trustee of IP Portfolio of First-in-Class Non-Opioid Analgesic in c...
Published : 23 Dec 2024
Read MoreAagami Updates of 2024Brought successes for clients 2 investments including from Corporate Venture of a global pharma, for US clients Novel and P...
Published : 19 Dec 2024
Read MoreAagami, Inc. are pleased to announce that our US client has awarded a contract expansion extension to support them in JV/Acquisition/Investment initia...
Published : 14 Nov 2024
Read MoreAs we all know, JP Morgan Healthcare (JPM) week is an annual pilgrimage. Aagami team is already geared up for participation including Biotech Showcase...
Published : 01 Nov 2024
Read MoreAagami has received another contract extension from Japanese client specialising in Nose to Brain delivery.. The client has unlocked efficient de...
Published : 15 Oct 2024
Read MoreWe are very pleased to announce that we had added another Japanese client to Aagami family. Client is a Japan based company specializing in Contr...
Published : 01 Oct 2024
Read MoreAagami is pleased to announce that during the period of July to September, multiple clients have awarded contract extensions to Aagami.US based Geneti...
Published : 16 Sep 2024
Read More